Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2025.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
- Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty
- Fulcrum Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Fulcrum Therapeutics price target lowered to $20 from $26 at Oppenheimer
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
